/주식/PCRX
PCRX

PCRX

USD

Pacira BioSciences Inc. Common Stock

$24.450+0.100 (0.411%)

실시간 가격

Healthcare
Drug Manufacturers - Specialty & Generic
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$24.350

고가

$24.590

저가

$23.500

거래량

0.18M

기업 기본 정보

시가총액

1.1B

산업

Drug Manufacturers - Specialty & Generic

국가

United States

거래 통계

평균 거래량

0.89M

거래소

NMS

통화

USD

52주 범위

저가 $11.16현재가 $24.450고가 $29.61

관련 뉴스

GlobeNewswire

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

PHILADELPHIA, May 26, 2025 (GLOBE NEWSWIRE) -- DoubleVerify Holdings, Inc. (NYSE:DV): If you have held DoubleVerify Holdings, Inc. (NYSE:DV) shares since prior to November 10, 2023, and would like to learn

더 보기
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
GlobeNewswire

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at

더 보기
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee